Inno­v­a­tive organ-on-chip spe­cial­ist Dynamic42 GmbH has closed a mid-seven-fig­ure financ­ing round. The com­pany, which was spun off from the “Cen­ter of Sep­sis Con­trol and Care” of the Uni­ver­sity Hos­pi­tal Jena in March 2018, was able to con­vince both the pre­vi­ous lead investor bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm‑t) and a fam­ily office from the health sec­tor to invest and sup­port the growth, devel­op­ment and vision of the com­pany in the com­ing years as part of a growth financ­ing round (Series A). 

Deci­sive for the invest­ment was above all the added value that Dynamic42 gen­er­ates with its tech­nol­ogy and its use for soci­ety, such as the increase of drug safety, the reduc­tion of drug devel­op­ment costs and the reduc­tion of ani­mal test­ing. Here, Dynamic42´s tech­nol­ogy offers a very good alter­na­tive to cur­rent sys­tems used in the devel­op­ment of active com­pounds and has a high mar­ket poten­tial. “We can proudly announce that we have cre­ated an up-and-com­ing com­pany and are extremely pleased about this strate­gi­cally impor­tant invest­ment. In times of a more chal­leng­ing invest­ment mar­ket, it is a strong sig­nal for us that our tech­nol­ogy and vision pos­sess high poten­tial,” said Man­ag­ing Direc­tors Dr. Mar­tin Raasch and Dr. Knut Rennert.

Flex­i­ble and cus­tomized Organ-on-Chip Solu­tions for Advanced Drug Testing

Dynamic42 offers its cus­tomers minia­tur­ized human organ mod­els (so-called organ-on-chip/ micro­phys­i­o­log­i­cal sys­tems) for drug test­ing. Dynamic42 is unique on the mar­ket due to its flex­i­ble and eas­ily cre­ated cus­tomer-spe­cific solu­tions based on its inno­v­a­tive tech­nol­ogy plat­form. In addi­tion, Dynamic42 is able to inte­grate essen­tial com­po­nents of the human immune sys­tem into its human organ mod­els and to inves­ti­gate their influ­ence on drug com­pat­i­bil­ity. Cus­tomers can thus make ini­tial judge­ments about the tox­i­c­ity of drug can­di­dates in humans even before ani­mal test­ing in the pre­clin­i­cal phase of drug devel­op­ment and decide whether to con­tinue or stop the devel­op­ment of an active substance.

“Dynamic42 GmbH has grown steadily since it was founded five years ago and has already been able to win well-known phar­ma­ceu­ti­cal com­pa­nies as cus­tomers. We are con­vinced that Dynamic42, with its strong tech­nol­ogy plat­form and moti­vated team, will play a lead­ing role in the rapidly grow­ing organ-on-chip mar­ket in the future,” said Ste­fan Jahn, Senior Invest­ment Man­ager at bm‑t.

With the invest­ment, Dynamic42 will con­tinue the fur­ther devel­op­ment of prod­ucts and ser­vices, open new mar­kets, recruit highly qual­i­fied per­son­nel, fur­ther develop the com­pany infra­struc­ture as well as expand the prop­erty rights port­fo­lio and sales infra­struc­ture. An impor­tant mile­stone in the com­ing years will be the company´s inter­na­tion­al­iza­tion, includ­ing enter­ing the USA as the world’s largest phar­ma­ceu­ti­cal market.

About Dynamic42 GmbH

Dynamic42 GmbH was founded in 2018 and is a spin-off from the Inte­grated Research and Treat­ment Cen­ter for Sep­sis Con­trol and Care (CSCC) of the Uni­ver­sity Hos­pi­tal Jena. Dynamic42 mar­kets and devel­ops human organ-on-chip models/ micro­phys­i­o­log­i­cal sys­tems with inte­grated immune sys­tem com­po­nents for research and test­ing of phar­ma­ceu­ti­cal prod­ucts, novel ther­a­pies such as nanopar­ti­cles, chem­i­cal and food additives.

About bm‑t

bm‑t is one of the top addresses for invest­ments in Thuringia. The entrusted cap­i­tal is prof­itably invested by bm‑t in start-up teams and com­pa­nies in the Free State of Thuringia. bm‑t cur­rently man­ages eleven funds with a total vol­ume of over 415 mil­lion euros and invests in inno­v­a­tive com­pa­nies in almost all sec­tors and in all phases of cor­po­rate devel­op­ment — from the start-up and growth phases to com­pany suc­ces­sions and buyouts.